Replies to post #1261 on Enanta Pharmaceuticals Inc (ENTA)

[NY1972]

ENTA is planning a EDP-239 + EDP-494 combo, their version of Havoni

"Enanta has also discovered EDP-239, an NS5A inhibitor for HCV infection. EDP-239 has successfully completed phase 1 studies in 2015, including a proof-of-concept study, but its further development will depnd upon its potential utility as an additional component of an EDP-494 containing therapy, which will be determined after early clinical trials of EDP-494"